Intuniv

Guanfacine, the active ingredient in Intuniv, is a Alpha-2A adrenergic agonist presented as a extended-release tablet for oral use. It treats attention deficit hyperactivity disorder (ADHD) and hypertension in children, adolescents, and adults.

GNH USA supplies Intuniv as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Intuniv (guanfacine) is used in conditions involving central nervous system regulation and vascular tone.

- Attention deficit hyperactivity disorder (ADHD): improves attention, reduces hyperactivity and impulsivity. - Hypertension: lowers blood pressure by decreasing sympathetic outflow.

Common side effects are generally mild and may resolve with continued therapy.

Common Side Effects: - Drowsiness - Dry mouth - Fatigue - Headache - Dizziness - Nausea

Serious or Rare Side Effects: - Severe hypotension - Bradycardia - Syncope - Heart block - Liver function abnormalities - Allergic reactions such as rash or angioedema

Intuniv should be used with careful monitoring and appropriate patient counseling.

- Monitor blood pressure: check regularly during initiation and dose adjustments. - Assess heart rate: watch for bradycardia, especially in patients with cardiac history. - Avoid abrupt discontinuation: taper under medical supervision to prevent rebound hypertension. - Caution in hepatic impairment: dose may need adjustment due to altered metabolism. - Avoid concomitant use with strong CYP3A4 inhibitors: may increase guanfacine exposure. - Store at ambient temperature: keep in the original pack, protect from moisture.

Intuniv may interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may cause excessive guanfacine levels. - Antihypertensive agents (e.g., clonidine, beta‑blockers): additive hypotensive effect. - Sedatives (e.g., benzodiazepines): increased central nervous system depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effectiveness. - Antidepressants (e.g., SSRIs): may alter blood pressure response. - Diuretics: may enhance hypotensive effect.